Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..5 of 5 - per page
Order by
A liquid system which enables rapid transmigration of therapeutic doses of up to large molecules More
A new veterinary medicinal composition designed to maintain the oxygenic consumption, to restore hydric, electrolytic and energetic status, as well as the blood pH in affected mammals. More
A novel non-invasive method for using carbon-13 magnetization transfer effects to determine and evaluate in vivo aspartate transaminase (AST) activity and levels in an organ, as a biomarker of disease and certain neurological disorders. More
VEGF111, a novel naturally occurring isoform of human VEGF-A, was recently cloned. VEGF111 is active in terms of activation of VEGF receptors, induction of endothelial cells multiplication and stimulation of vascularisation in vitro and in vivo. As r More
A Minimally Invasive, Laser-Based Therapeutic Approach for the treatment of Abdominal Aortic Aneurysm (AAA). keywords: Irradiation More
Displaying 1..5 of 5 - per page
Order by
Partnering consultation free of charge
Molecular Diagnostics Conference
EuroPLX 37/EuroPLX 38
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us